98%
921
2 minutes
20
In the context of ulcerative colitis (UC), iron deficiency anemia (IDA) is often presented as a prevalent systemic manifestation. However, there is an absence of an effective strategy for the specific case of UC with IDA. Herein, mendelian randomization (MR) analysis is applied to confirm the causal association between UC and iron-related conditions. Accordingly, we have developed a probiotic-based therapeutic approach that synergistically alleviates inflammation and IDA. Probiotic Nissle 1917 (EcN) is functionalized by the FeO nanoenzyme and hyaluronan (HA) through electrostatic layer-by-layer (LBL) adsorption. As expected, the obtained EcN@FeO/HA exhibits excellent properties in vitro, such as gastric acid resistance and ROS-scavenging capability. Upon oral administration, EcN@FeO/HA shows remarkable adhesion in vivo, particularly in inflamed mice. Moreover, EcN@FeO/HA shows a "two birds with one stone" effect in dextran sulfate sodium (DSS)-induced mice. First, it exerts anti-inflammatory effects through promoting the expression of tight junction proteins and regulating the gut microbiota. Second, it addresses the issue of IDA. EcN@FeO/HA effectively ameliorates IDA in DSS-induced mice through iron supplementation, EPO upregulation, and iron homeostasis modulation, resulting in enhanced RBC morphology and elevated cell counts. Therefore, the proposed strategy provides inspiration for future management of diseases and related complications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsami.5c04452 | DOI Listing |
J Med Chem
September 2025
State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Resistance-conferring mutations in the androgen receptor (AR) ligand-binding pocket (LBP) compromise the effectiveness of clinically approved orthosteric AR antagonists. Targeting the dimerization interface pocket (DIP) of AR presents a promising therapeutic approach. In this study, we report the design and optimization of -(thiazol-2-yl) furanamide derivatives as novel AR DIP antagonists, among which was the most promising candidate.
View Article and Find Full Text PDFLymphat Res Biol
September 2025
Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Venous malformations can cause substantial morbidity and long-term complications. There are no Food and Drug Administration (FDA)-approved therapies for the treatment of venous malformations. However, off-label use of sirolimus has demonstrated clinical benefit in these patients.
View Article and Find Full Text PDFIntern Med J
September 2025
Lyell McEwin Hospital, Adelaide, South Australia, Australia.
Where possible, antimicrobials, such as clindamycin, should be given orally rather than intravenously when efficacy will be equivalent. A single-centre pre-/post-intervention study was conducted. There were 11 134 patients admitted to included wards during the study period.
View Article and Find Full Text PDFMinerva Pediatr (Torino)
September 2025
Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, San Marco Hospital, University of Catania, Catania, Italy.
Allergen immunotherapy (AIT) is the only treatment capable of modifying the natural history of allergic diseases by promoting immune tolerance. Initially developed for respiratory allergies, AIT has expanded to include food allergies, particularly through oral immunotherapy (OIT). This review explores the historical evolution, current applications, and future directions of AIT in pediatric patients.
View Article and Find Full Text PDFClin Transl Allergy
September 2025
Second Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.
Background: Induced sputum cell count is crucial for assessing airway inflammatory phenotypes. This study investigated how aspirin-induced bronchospasm affects sputum cell counts in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD), comparing systemic versus local aspirin administration.
Methods: Seventy-eight patients with N-ERD and 39 with aspirin-tolerant asthma (ATA) participated.